Correlation between osteoarthritis and monocyte chemotactic protein-1 expression: a meta-analysis
Feifei Ni1, Yanchao Zhang2, Xiaoxiao Peng3
1Department of Orthopaedics, Shengjing Hospital of China Medical University, Sanhao Street No. 36, Heping District, Shenyang, 110004, Liaoning, People's Republic of China.
Journal of Orthopaedic Surgery and Research
|November 10, 2020
Summary
Monocyte chemotactic protein-1 (MCP-1) levels are elevated in osteoarthritis patients compared to healthy individuals. Higher serum MCP-1 may indicate osteoarthritis, suggesting its role in disease progression.
Area of Science:
- Biochemistry
- Immunology
- Orthopedics
Background:
- Osteoarthritis (OA) is a degenerative joint disease with complex pathogenesis.
- Monocyte chemotactic protein-1 (MCP-1) is a key chemokine involved in inflammatory processes.
Purpose of the Study:
- To evaluate the association between MCP-1 and osteoarthritis through a meta-analysis.
- To determine if MCP-1 levels can serve as a diagnostic biomarker for OA.
Main Methods:
- A systematic literature search was conducted across multiple databases (PubMed, Embase, etc.) before May 2020.
- Meta-analysis was performed using STATA and Revman, calculating standard mean differences (SMDs) and 95% confidence intervals (CIs).
- Nine clinical studies involving 376 OA patients and 306 healthy controls were analyzed.
Main Results:
- MCP-1 expression levels were significantly higher in OA patients than in healthy controls (SMD = 1.97, p = 0.003).
- Serum MCP-1 levels were significantly elevated in OA patients (SMD = 2.83, p < 0.00001), but not in synovial fluid or cartilage.
- Subgroup analysis indicated higher MCP-1 levels in Asian and mixed populations, and specifically in Chinese, Dutch, and Brazilian OA patients.
Conclusions:
- MCP-1 expression is significantly higher in individuals with osteoarthritis.
- MCP-1 may play a crucial role in the pathogenesis and progression of osteoarthritis.
- Serum MCP-1 shows potential as a biomarker for osteoarthritis diagnosis.
